Research ArticleALLERGY

Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

See allHide authors and affiliations

Science Translational Medicine  23 Oct 2019:
Vol. 11, Issue 515, eaax2945
DOI: 10.1126/scitranslmed.aax2945

Interrupting inflammation in atopic dermatitis

The alarmin cytokine IL-33 is implicated in a variety of conditions, including atopy, and is an emerging therapeutic target. Chen et al. report a clinical trial of a single dose of an anti–IL-33 antibody (etokimab) in adults with moderate to severe atopic dermatitis. The trial design included a placebo condition and assessment of skin immune responses to challenges with house dust mite. Clinically, anti–IL-33 was well tolerated and reduced peripheral eosinophils and symptoms of atopic dermatitis. Blocking IL-33 interfered with neutrophil recruitment. These results reveal human immunobiology and demonstrate that anti–IL-33 is a promising therapeutic for atopic dermatitis.

View Full Text

Stay Connected to Science Translational Medicine